Bms-907351
Endometrial Carcinoma
M.D. Anderson Cancer CenterPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
230 Active assets in the Endometrial Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Indocyanine Green Istanbul University | Phase 4 | BB |
Inno-206 AstraZeneca | Phase 3 | BB |
Olaparib Qilu Pharmaceutical Co., Ltd. | Phase 4 | BB |
Palbociclib University Medical Center Groningen | Phase 4 | BB |
FILGRASTIM Mayo Clinic | Phase 3 | B |
View all 50 →
Same molecule, other indications
Bms-907351 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →